Chart to divest cryobiological products business

The sale is expected to close early in 4Q20, following the satisfaction of customary closing conditions, including regulatory requirements.

The strategic decision to divest the cryobiological products business reflects Chart’s strategy and capital allocation approach to focus on its core capabilities and offerings while continuing to expand its presence in clean energy applications including LNG, hydrogen, biogas/biomethane, carbon capture and other renewable fuelling sources.

This divestiture follows the 2018 sale of the company’s oxygen-related products business, which at the time was a portion of the previous BioMedical segment.

Chart confirmed that its medical oxygen related products for critical care applications such as COVID-19 will remain with the Chart business, as they are bulk, microbulk and mobile equipment that serve various industrial gas applications in addition to medical grade oxygen.

“This is a logical next step in our strategy to stay disciplined in our core cryogenic businesses that share common customers, technologies and end markets. Having a strategic life sciences buyer like Cryoport will provide a platform for the cryobiological products business to grow in medical and animal breeding spaces that are non-core to Chart,” said Jill Evanko, Chart’s President and Chief Executive Officer. “We will initially utilise the proceeds from the sale to pay down debt and subsequently continue to expand our presence, both organically and inorganically, into our high-growth focus areas, including hydrogen, carbon capture and other specialty markets.”

Read the article online at: https://www.hydrocarbonengineering.com/the-environment/26082020/chart-to-divest-cryobiological-products-business/